Solstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
ParticipantActivity from announced rounds
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.